Nurix therapeutics reports fourth quarter and fiscal year 2022 financial results and provides a corporate update

Demonstrated nx-2127 overcomes btk inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies

NRIX Ratings Summary

NRIX Quant Ranking